Working towards the next breakthrough in inflammation
– Meet the people behind our treatment pipeline
Nicolai works in inflammation research at Novo Nordisk
In the film below, Vice President of Inflammation Research, Nicolai Wagtmann tells us about the hopes and challenges of developing novel treatment options for chronic autoimmune inflammatory conditions like rheumatoid arthritis.
As a leader, Nicolai seeks to bring the range of experts both inside and outside the company together. This is to create a rich working environment focused on finding better treatment solutions for people living with chronic inflammation, by applying a keen understanding of complex immunological science.
A realistic optimist seeks to make a difference
Inflammation research at Novo Nordisk
Compared to diabetes, rheumatoid arthritis and other chronic autoimmune inflammatory conditions represent a relatively new research and development focus for Novo Nordisk.
We are building a portfolio of novel treatment targets in inflammation for rheumatoid arthritis and Crohn's disease, as well as other such conditions.
Other portraits in this series
|Haemophilia research||diabetes research||Device|